

June 25, 2025
PDRadiopharma Inc.

PDRadiopharma Inc. Announcement of the Releases of "AMYfollow™": Software for Supporting Longitudinal Reporting of Amyloid PET Imaging

**This release is an English translation of “アミロイドPET 画像の経時変化レポート作成支援ソフトウェア「AMYfollow™」リリースのお知らせ”, with a priority given to Japanese for content and interpretation.*

TOKYO, JAPAN – June 25, 2025 - PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo) today announced the release of "AMYfollow™", a software tool assists in creating longitudinal reports by displaying side-by-side PET images (before and after treatment) obtained from amyloid PET scans using "AMYViD® Injection"※1.

Key Features of AMYfollow™:

- **Support for Creating Longitudinal Reports of Amyloid PET Images Before and After Treatment**

The software assists in creating reports by displaying side-by-side images obtained from PET scans conducted before and after treatment with anti-amyloid-beta antibody therapies, along with the Centiloid scale※2.

- **Easy-to Understand Reports for Clinical Communication**

The intuitive, visually accessible reports can aid in explaining results to patients and facilitate efficient information sharing among healthcare professionals.

The software is available upon request to medical institutions using AMYViD® Injection.

PDRadiopharma Inc. remains committed to advancing solutions that support accurate diagnosis and effective treatment. Through initiatives such as **AMYfollow™**, we aim to improve dementia care, support the realization of a healthy longevity society, and deliver meaningful value to patients, their families, and the broader community affected by dementia.

※1 Generic name: Florbetapir (18F). Florbetapir (18F), labeled with radioactive fluorine (18F), is a PET imaging agent developed to visualize amyloid beta plaques in the human brain. It received its first manufacturing and marketing approval in Japan in December 2016 as a "Flexible Dose™ formulation," distinct from conventional radiopharmaceuticals. Amyvid and AMYViD are registered trademarks of Avid Radiopharmaceuticals, Inc.

※2 Centiloid scale: The Centiloid scale is a way to measure how much amyloid-beta (Aβ) protein has built up in the brain. The scale goes from 0 to 100. A score of 0 means the brain is similar to that of a young, healthy person with little or no Aβ. A score of 100 is the average level found in people with Alzheimer's disease. The higher the number, the more Aβ is present in the brain

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 22 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit <https://www.pdradiopharma.com/>

Inquiries:

PDRadiopharma Inc.

Contact: Akiko Murakami, General Affairs

Email: s-info-hq@pdradiopharma.com